培莫沙肽治疗非透析慢性肾脏病贫血的随机试验
这项在中国38个中心开展的随机、活性对照、开放标签、非劣效性3期研究纳入173例非透析依赖性慢性肾脏病贫血患者,比较培莫沙肽每4周皮下注射与阿法依泊汀每周或每两周给药的疗效。结果显示,培莫沙肽组血红蛋白平均变化为19.2 g/l,阿法依泊汀组为15.4 g/l,组间差异3.8 g/l(95%CI:0.7-6.9),达到非劣效标准。两组不良事件和严重不良事件发生率相似,最常见药物相关不良事件为高血压,未观察到药物相关超敏反应或致死事件。
要点
- 培莫沙肽每4周皮下注射在提升和维持血红蛋白方面非劣效于阿法依泊汀。
- 培莫沙肽组血红蛋白平均变化19.2 g/l,阿法依泊汀组15.4 g/l,组间差异3.8 g/l(95%CI:0.7-6.9)。
- 两组不良事件和严重不良事件发生率相似,最常见药物相关不良事件为高血压。
核心结论
- 培莫沙肽在非透析依赖性慢性肾脏病贫血患者中提升和维持血红蛋白的疗效与阿法依泊汀相当,且未发现新的安全性问题。
研究设计与样本
- 随机、活性对照、开放标签、非劣效性3期研究,在中国38个中心开展,173例患者至少接受1剂培莫沙肽(115例)或阿法依泊汀(58例)。
主要发现
- 疗效评估期间,培莫沙肽组血红蛋白较基线平均变化19.2 g/l,阿法依泊汀组15.4 g/l,组间差异3.8 g/l(95%CI:0.7-6.9)。
- 两组不良事件和严重不良事件发生率相似,最常见药物相关不良事件为高血压。
- 未观察到药物相关超敏反应或致死事件。
关键数值与推荐
- 非劣效性界值:双侧95%CI下限≥-10 g/l。
- 血红蛋白目标水平维持100至120 g/l,培莫沙肽每4周皮下注射于上臂,阿法依泊汀每周或每两周给药。
临床怎么用
- 对于非透析依赖性慢性肾脏病贫血患者,培莫沙肽每4周皮下注射可作为阿法依泊汀的替代选择,需将血红蛋白维持在100至120 g/l。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pegmolesatide has been recently approved for treating anemia in chronic kidney disease (CKD) patients in China. We presented the results of the pivotal study conducted in patients with nondialysis-dependent (NDD)-CKD with anemia. METHODS: This randomized, active-controlled, open-label, noninferiority phase 3 study was conducted across 38 centers in China. Eligible patients were randomly assigned to receive subcutaneous injection of pegmolesatide in the upper arm once every 4 weeks or epoetin alfa weekly or biweekly, with doses adjusted to maintain hemoglobin (Hb) level of 100 to 120 g/l. The primary outcome was the mean change in Hb level from the baseline during the efficacy evaluation period. Noninferiority of pegmolesatide to epoetin alfa was established if the lower limit of the 2-sided 95% confidence interval (CI) was ≥ -10 g/l. RESULTS: A total of 173 patients received at least 1 dose of pegmolesatide (115 patients) or epoetin alfa (58 patients). During the efficacy evaluation period, the mean change in Hb from baseline level was 19.2 g/l in the pegmolesatide group and 15.4 g/l in the epoetin alfa group with a between-group difference of 3.8 g/l (95% CI: 0.7-6.9). The incidence of adverse events (AEs) and serious AEs (SAEs) were similar between groups, with hypertension being the most reported AE related to the study drug. No drug-related hypersensitivity reactions or fatal events were observed. CONCLUSION: Pegmolesatide demonstrated comparable efficacy to epoetin alfa in elevating and maintaining Hb levels in patients with NDD-CKD with anemia without new safety concerns (ClinicalTrials.gov identifier: NCT03903809).
引用
- Xie J, Yang A, Qiu H, et al. Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD. Kidney Int Rep. 2024. PMID: 40225393. doi:10.1016/j.ekir.2024.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。